Abbott Sees Atrasentan Market Opportunity In Less Advanced Prostate Cancer
Executive Summary
Abbott sees a market opportunity for atrasentan in prostate cancer patients with less advanced disease based on the company's initial subset analysis of an unfavorable Phase III study for the endothelin-1 receptor antagonist
You may also be interested in...
Abbott Xinlay Review By Oncologic Committee Expected In Mid-September
Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September
Abbott Xinlay Review By Oncologic Committee Expected In Mid-September
Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September
AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success
AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix